Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20964640 | 0.87 | MEN1 (0.53) | KDM4ERAB9ANPC1KMT2AMEN1 | |
| SCHEMBL9313923 | 0.81 | MEN1 (0.68) | KDM4ERAB9ANPC1KMT2AMEN1 | |
| SCHEMBL30022414 | 0.80 | RAB9A (0.54) | KDM4ERAB9ANPC1KMT2AMEN1 | |
| SCHEMBL22722429 | 0.79 | POLB (0.59) | KDM4ERAB9ANPC1KMT2AMEN1 | |
| SCHEMBL10176583 | 0.79 | MEN1 (0.59) | KDM4ERAB9ANPC1KMT2AMEN1 | |
| SCHEMBL7264600 | 0.79 | ALDH1A1 (0.73) | KDM4ERAB9ANPC1KMT2AMEN1 | |
| SCHEMBL31570084 | 0.77 | MEN1 (0.57) | KDM4ERAB9ANPC1KMT2AMEN1 | |
| SCHEMBL9292088 | 0.77 | MEN1 (0.57) | KDM4ERAB9ANPC1KMT2AMEN1 | |
| SCHEMBL22722430 | 0.77 | POLB (0.61) | KDM4ERAB9ANPC1KMT2AMEN1 | |
| SCHEMBL23130363 | 0.76 | RAB9A (0.53) | KDM4ERAB9ANPC1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190127361-A1 | Therapeutic Compounds | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2019-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190127361-A1 | Therapeutic Compounds | SDHA, SLC10A1, SERPINC1 | KDM4E 4616/4885RAB9A 426/4885NPC1 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.